Global CAR T Cell Therapy market is projected to exceed USD 2.99 Billion by the year 2025, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2018-2025.
The CAR T therapy utilizes the patient’s immune system and builds it to target cancer cells & execute them. The therapy is based on the T-cells re-engineering making them identify tumor cells and target those cells when they usually cannot do so. The CAR T has proved very effective in patients affected by blood cancer who already have received alternative treatments such as chemotherapy.
The selection of the target antigen to determine the therapy type:
The CD19 antigen existing on the exterior of the B cell has demonstrated to be the extremely effective CAR T cell therapy with accepted treatment for lymphoma and leukemia where B cells have become cancer-causing. At present, Novartis’ Kymriah and Kite Pharma’s Yescarta are the only permitted products for treating Acute B Cell Lymphoblastic Leukemia & Large B-Cell lymphoma respectively. Distinguished players in this sector are developing novel CAR-T therapies aiming different antigens for blood cancers including BCMA, CD22, CD123, and for solid tumor including MUC16, L1CAM, among others, cites the report.
Global Market Importance:
CAR T is an immensely innovative therapy which encompasses a distinct business model in the medicinal industry to attain the profitable stage. This therapy indicates a new method with massive potential in terms of production process and toxicity administration. Top industry contenders such as Celgene, Gilead, Novartis, and others are getting complete exposure to the immuno-oncology domain with the current product developments, merger & acquisition activities, and clinical trials to amplify the significance of cellular therapy.
Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695130/
According to the report, the global market has been bifurcated based on the application, geography, and target antigen. With regards to target antigen, the market is split into EGFRV III, CD19, MESO, CD20, HER2, and others. Based on application, the global CAR T Cell Therapy business space is categorized into Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, and others. The report cites that the first therapy permitted was observed amid young adults and/or pediatrics Acute Lymphoblastic Leukemia an illness with a massive unmet requirement where CAR-T showed high efficacy. The treatment for Diffuse Large B-Cell Lymphoma was anticipated to hold the biggest share of the market precede by the multiple myeloma. Furthermore, follicular lymphoma and Chronic Lymphocytic Leukemia are predicted to amass lucrative gains during the projection timeframe.
Speaking of regional landscape, North America is projected to lead the CAR T cell therapy market in the coming years. This growth can be accredited to burgeoning research & developments programs along with ongoing regulatory sanctions, cites the report. For example, Kymriah (a product by Novartis) has attained the USFDA sanction in August 2017 for treating patients affected with acute lymphoblastic leukemia. Additionally, market leaders such as Kite and Novartis first reached the American market and are anticipated to concentrate on expansion through the academic centers which can offer optimal cancer treatment in the year 2018.
The key players profiled in the CAR T cell therapy market are Kite Pharma, Inc., Celgene Corporation, Novartis International AG, Juno Therapeutics, Sorrento Therapeutics, Pfizer, Inc. Cellectis, Immune Therapeutics, and Bluebird bio. As per the report findings, these key players focus on delivering better chronic care administration at affordable charges.